Earnings

Kura Oncology's KOMZIFTI Sales Grow 53% in Third Quarter

The Tip Desk · November 12, 2026 · 3 min read

Net product revenue reached $13.9 million as new patient starts rose 30% and total prescriptions 65% sequentially.

Kura Oncology, Inc. (KURA), a biopharmaceutical company focused on precision medicines for cancer, reported third-quarter 2026 net product revenue of $13.9 million for KOMZIFTI (ziftomenib), a 53% sequential increase from $9.1 million in the second quarter.

The menin-inhibitor launch continued to build volume. New patient starts were approximately 150, up 30% from about 115 in the prior quarter. Total prescriptions, including repeats, were more than 420, up 65% from more than 250.

The company said KOMZIFTI maintained a majority share of new patient starts in the relapsed or refractory NPM1-mutated AML menin inhibitor class. President and Chief Executive Officer Troy Wilson said the results “demonstrate the growing commercial potential of KOMZIFTI” and provide a foundation as the company advances ziftomenib into frontline AML.

Total revenue was $22.8 million, compared with $20.8 million a year earlier, as product sales offset a decline in collaboration revenue. Collaboration revenue was $8.9 million, down from $20.8 million in the third quarter of 2025.

Research and development expenses were $66.9 million. Selling, general and administrative expenses were $30.2 million. Net loss was $70.2 million, or $0.78 a share, compared with $74.1 million, or $0.85 a share, a year earlier. The loss included $8.2 million of non-cash share-based compensation.

Cash, cash equivalents and short-term investments were $492.1 million as of September 30, 2026.

Kura entered a strategic financing agreement with affiliates of Oberland Capital providing up to $300 million in potential funding, including up to $275 million in debt and $25 million in equity, subject to conditions. The company received $55 million at closing, comprised of $50 million in debt funding before fees and a $5 million equity investment. The debt agreement has a seven-year term, with interest between 6.95% and 8.95% and 50% of interest capitalized during the first three years after each advance. The financing also provides a single-digit royalty tied to U.S. KOMZIFTI net sales, capped at 20% of aggregate term-loan principal.

The company said the financing is expected to support continued investment in KOMZIFTI, ziftomenib development, and darlifarnib monotherapy registrational and combination studies. Additional funding is available through company-option and milestone-based tranches, and another tranche is available upon mutual agreement.

Kura said it reached FDA alignment on the design of a planned single-arm monotherapy registrational study of darlifarnib in approximately 40 patients with HRAS-mutant salivary gland cancer, with initiation targeted for the first half of 2027. Combination studies of darlifarnib in renal cell and pancreatic cancers are expected to reach key development milestones in 2027.

Site activation and enrollment continue in the Phase 3 KOMET-017 frontline registrational program with ziftomenib-based combinations in newly diagnosed AML. Initial topline results from that program are anticipated in 2028. Eight ziftomenib abstracts are scheduled for ASH 2026, including two oral presentations on FLT3 inhibitor combinations.

Kura’s 2026 collaboration revenue guidance is $40 million to $45 million, and the company is maintaining guidance of $90 million to $110 million in each of 2027 and 2028. The company said that guidance reflects non-cash accounting recognition under its agreement with Kyowa Kirin and does not reflect the timing of cash receipts. Anticipated collaboration milestone payments from Kyowa Kirin total $180 million.

Based on its current operating plan, Kura expects its financial resources to support operations beyond anticipated initial topline results from the pivotal Phase 3 KOMET-017 study in 2028.

Jennifer Fulk joined as chief financial officer in September 2026. The company also launched Caspian Therapeutics, a separately financed company established to advance menin inhibitors for diabetes and cardiometabolic diseases; Caspian completed a $50 million financing led by BVF Partners.

More on KURA

September 28, 2026 QBook Stronger demand supports expansion as pricing diverges

Kura Oncology, Inc. — all coverage and financials